HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Research Dictionary Pharma Mobile

Sign Up FREE or Login

N- (4- ((3,4- dichloro- 6- fluoro- phenyl)amino)quinazoline- 6- yl)- 2- chloroacetamide

Subscribe to New Research on N-(4-((3,4-dichloro-6-fluoro-phenyl)amino)quinazoline-6-yl)-2-chloroacetamide

Also Known As:

MLO5 compound; TKS050

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 60
- 2-Ring Heterocyclic Compounds
  - Quinazolines: 29
    - N-(4-((3,4-dichloro-6-fluoro-phenyl)amino)quinazoline-6-yl)-2-chloroacetamide: 1

Experts

1.	Klein, Benjamine Y: 1 article (01/2007)
2.	Mishani, Eyal: 1 article (01/2007)
3.	Shushan, Asher: 1 article (01/2007)
4.	Ben-Bassat, Hannah: 1 article (01/2007)
5.	Rojansky, Nathan: 1 article (01/2007)
6.	Laufer, Neri: 1 article (01/2007)

Related Diseases

1.

Leiomyoma (Uterine Fibroids)

01/01/2007 - "Leiomyoma cell growth is effectively blocked by TKS050 and genistein. "
01/01/2007 - "TKS050 (2 micromol/L) and genistein (50 micromol/L) completely suppressed leiomyoma cell proliferation, and the cells did not recover after cessation of treatment. "
01/01/2007 - "Inhibition of leiomyoma cell proliferation in vitro by genistein and the protein tyrosine kinase inhibitor TKS050."
01/01/2007 - "To determine the potency of TKS050, a new epidermal growth factor receptor (EGFR) inhibitor and genistein, a naturally occurring protein tyrosine kinase inhibitor, to inhibit leiomyoma cell proliferation in vitro. "

Related Drugs and Biologics

1.	Genistein
2.	Epidermal Growth Factor Receptor (EGF Receptor)
3.	Protein-Tyrosine Kinases (Tyrosine Kinase)

Related Therapies and Procedures

1.	Withholding Treatment